Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Protalix BioTherapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Company's New Drug Application (NDA) for taliglucerase alfa for the treatment of Gaucher disease. Taliglucerase alfa is a plant-cell expressed form of glucocerebrosidase (GCD).

25 Feb 2011

Research sheds new light on problem of insulin resistance in type 2 diabetes

A research team, led by La Jolla Institute scientist Joel Linden, Ph.D., has shed new light on the problem of insulin resistance, and identified the key participants in a molecular pathway that holds therapeutic promise for reducing the severity of type 2 diabetes.

25 Feb 2011

More than one way to silence gene activity

There's more than one way to silence gene activity, according to a Michigan State University researcher.

25 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Isis Pharmaceuticals, Inc. announced today the results from a Phase 1 clinical trial in which ISIS-CRPRx produced statistically significant reductions in C-reactive protein in the cohort of subjects in the study with elevated CRP.

24 Feb 2011

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.

24 Feb 2011

Bunion deformity more frequent in women, greatly reduces general, foot-specific HRQOL

New research determined that an increase in the severity of hallux valgus, or bunion deformity, progressively reduced both general and foot-specific health related quality of life. Bunion deformity was found in 36% of the study population and occurred more frequently in women and older individuals. Pain in other parts of the body beyond the foot was associated with increased bunion severity.

24 Feb 2011

Prevalence of bunions increases with age; More common in women

New research determined that an increase in the severity of hallux valgus, or bunion deformity, progressively reduced both general and foot-specific health related quality of life (HRQOL). Bunion deformity was found in 36% of the study population and occurred more frequently in women and older individuals.

23 Feb 2011

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors or multiple myeloma, which compared XGEVA to Zometa in preventing skeletal-related events.

23 Feb 2011

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.

22 Feb 2011

New Harris Poll suggests that many doctors dont help obese patients to lose weight

A new Harris Poll suggests that many doctors are doing little or nothing to help their overweight patients to lose weight.

22 Feb 2011

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema.

22 Feb 2011

$Tip sheets provide details on hip and knee fracture treatment$

Tip sheets provide details on hip and knee fracture treatment

Patients who wait more than 36 hours for surgery to correct a hip fracture have a 39 percent rate of medical complication and those who wait 48 hours have a 46 percent complication rate. Patients who receive surgical treatment within 24 hours have a lower complication rate of 25 percent and a shorter hospital stay. Each day the surgery was delayed added an additional two days to hospital stay.

21 Feb 2011

'Experience station' program offers rheumatologists to gain insight into patients' everyday challenges

Pharmaceutical companies are focusing on more unique approaches in the development of educational and experiential solutions for their health care customers at medical conferences, according to Joe Scrocco, chief executive officer of OneWorld, Inc., a leading pharmaceutical consulting firm.

21 Feb 2011

Knee replacement surgery keeps one active even after 20 years: Study

A latest study has shown that patients with artificial knees were still functional after 20 years, even jogging or playing tennis. The researchers looked at people who had knee replacements between 1975 and 1989 in the state of Indiana and noted that they lived for another 20 years maintained an active lifestyle. All reported at least “moderate” activity.

20 Feb 2011

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Protalix BioTherapeutics, Inc., announced today that new clinical data from the switchover trial of taliglucerase alfa in Gaucher disease patients and preclinical data on oral enzyme glucocerebrosidase (oral GCD) will be presented today at the 7th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2011 in Las Vegas, Nevada.

19 Feb 2011

Patients who undergo orthopedic surgeries at high-volume hospitals have better outcomes

Patients who undergo elective orthopedic surgeries at high-volume, regional hospitals have better surgical outcomes and experience fewer complications than those who undergo those surgeries at local hospitals, according to research being presented by Hospital for Special Surgery investigators at the 2011 Annual Meeting of the American Academy of Orthopaedic Surgeons.

19 Feb 2011

New studies unveil latest information on hip care at AAOS meeting

At today's 2011 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) three new studies unveil the latest in hip care.

19 Feb 2011

New study identifies factors that predict dancer ability to return to work after hip arthroscopy

A new study has identified factors that predict the ability of a professional dancer to return to professional performance after hip arthroscopy surgery. The study by Hospital for Special Surgery investigators will be presented at the American Academy of Orthopaedic Surgeons annual meeting, held Feb. 15-19 in San Diego, Calif.

19 Feb 2011

Research suggests weight loss greatly improves knee pain related to OA

Knee pain related to osteoarthritis is a common complaint among obese individuals and retired professional athletes, especially former NFL players, but researchers presenting their work at the American Orthopaedic Society for Sports Medicine's Specialty Day program say they have a simple solution: lose weight.

19 Feb 2011

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Protalix receives FDA CRL for taliglucerase alfa NDA for Gaucher disease

Research sheds new light on problem of insulin resistance in type 2 diabetes

More than one way to silence gene activity

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

Bunion deformity more frequent in women, greatly reduces general, foot-specific HRQOL

Prevalence of bunions increases with age; More common in women

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

New Harris Poll suggests that many doctors dont help obese patients to lose weight

Pharming, Santarus begin RHUCIN Phase IIIb study in patients with Hereditary Angioedema

Tip sheets provide details on hip and knee fracture treatment

'Experience station' program offers rheumatologists to gain insight into patients' everyday challenges

Knee replacement surgery keeps one active even after 20 years: Study

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Patients who undergo orthopedic surgeries at high-volume hospitals have better outcomes

New studies unveil latest information on hip care at AAOS meeting

New study identifies factors that predict dancer ability to return to work after hip arthroscopy

Research suggests weight loss greatly improves knee pain related to OA

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in